P

Parabilis Medicines

Develops first-in-class cancer therapeutics

Associate Director, Toxicology

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • DVM or PhD in Toxicology, Pathology, Pharmacology, or a closely related discipline, with at least 8 years of industry experience in drug development.
  • Hands-on experience leading nonclinical safety programs from early discovery and lead optimization through IND filing; regulatory-only or late-stage-only experience is insufficient.
  • Experience supporting multiple modalities, including small molecules and at least one of siRNA/oligonucleotides, therapeutic peptides, PROTAC degraders, ADCs, or mRNA.
  • Experience with injectable drug products administered intravenously, subcutaneously, and/or intramuscularly, including familiarity with local tolerance study design and excipient/formulation safety assessment.
  • Ability to function as an independent scientific leader on project teams by setting strategy, driving decisions, and defending nonclinical positions.
  • Working knowledge of ICH guidelines M3(R2), S6(R1), S7A/B, S8, and S9; GLP regulations under 21 CFR Part 58; and FDA and EMA regulatory expectations for IND-enabling packages.
  • CRO management experience across GLP and non-GLP studies, with a track record of delivering high-quality IND-enabling packages on time.
  • Ability to author clear, regulatory-quality nonclinical documents and present complex data to diverse audiences.
  • Ability to work on site and attend in-person meetings.
  • Ability to travel up to 15%.

Responsibilities

  • Partner with discovery teams during Pre-LO and lead optimization to identify safety liabilities, design early safety profiling studies, and guide candidate selection through science-based risk assessment.
  • Serve as the primary toxicology lead on project teams, align Research and Clinical functions, and ensure integrated and timely IND readiness.
  • Develop and communicate candidate-specific toxicology risk assessments and go/no-go recommendations to project teams and leadership.
  • Apply knowledge of injectable formulations, including subcutaneous, intravenous, and intramuscular formulations, to anticipate and address local tolerance, excipient toxicity, and route-of-administration-specific safety considerations.
  • Design and oversee the complete IND-enabling nonclinical safety package, including acute and repeat-dose toxicology, safety pharmacology, genotoxicity, and local tolerance studies across relevant species.
  • In collaboration with the project team, select appropriate species, routes of administration, doses, and study durations based on scientific rationale and regulatory expectations.
  • Author and own nonclinical sections of INDs and CTAs, and support regulatory interactions.
  • Maintain awareness of evolving FDA, EMA, and ICH guidance and apply updates to program strategy.
  • Select and manage CROs and specialty contract laboratories for GLP and non-GLP preclinical studies.
  • Review study protocols, amendments, and final reports for scientific rigor, GLP compliance, and alignment with regulatory expectations.
  • Monitor study progress, interpret interim data, and make real-time scientific decisions to address unexpected findings or deviations.
  • Oversee test article logistics, dose formulation preparation and stability, and chain of custody in coordination with CMC and Pharmaceutical Sciences.
  • Define strategy, prioritize work, and resolve safety questions independently in close collaboration with the project team.
  • Communicate complex nonclinical safety data to internal project teams, senior leadership, and external partners.
  • Mentor junior scientists across the organization and contribute to scientific best practices.
  • Champion innovation in nonclinical safety tools and methodologies, including New Approach Methodologies, organoid/microphysiological systems, and in silico predictive models, to reduce animal use and accelerate timelines.

Desired Qualifications

  • DABT certification.
  • Familiarity with in vitro New Approach Methodology-based safety tools, including microphysiological systems, iPSC-derived models, and QSAR/in silico platforms.
  • Experience contributing to regulatory agency meetings, responding to nonclinical IND-related queries, and supporting due diligence and in-licensing evaluations.

About the Company

Parabilis Medicines

Develops first-in-class cancer therapeutics

Parabilis Medicines advances drug discovery for cancer by developing a novel class of therapeutics called Helicon therapeutics. Its lead candidate, FOG-001, is a first-in-class inhibitor that blocks TCF-mediated β-catenin signaling, aimed at targeting common yet hard-to-treat drivers of cancer. The company uses integrated technologies to speed up discovery and scale development from research through potential commercialization. Compared with peers, Parabilis emphasizes a unique mechanism (TCF/β-catenin pathway inhibition) and a platform-driven approach designed to accelerate progression toward precision cancer therapies. The goal is to shape the future of precision medicine by delivering new treatments for previously untreatable diseases and advancing into clinical development with impactful candidates.

Company size
201-500
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2016

Recently Posted Jobs

Explore more opportunities at Parabilis Medicines

See more jobs